The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Relevance of panobinostat-bortezomib-dexamethasone in R/R myeloma in the era of novel agents
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the results of a real-world study examining the role of the combination of panobinostat, bortezomib, and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma in 2022. The study found that this combination led to significant clinical responses in a small population. According to Dr Ramasamy, this combination should be considered in patients who have shown good prior responses with bortezomib, good bone marrow reserve, and without prior neuropathy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
